Brief: Anpac Bio Launches Novel Cancer Treatment Technology And Product Joint Venture
25/05/2021 12:15
May 25 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO LAUNCHES NOVEL CANCER TREATMENT TECHNOLOGY AND
PRODUCT
JOINT VENTURE - UTILIZING FINDINGS FROM 10 YEARS OF EARLY-STAGE
CANCER DETECTION WORK INVOLVING OVER 222,200 SAMPLE DATABASE
* ANPAC BIO-MEDICAL SCIENCE CO LTD - LABORATORY TESTS ON
NOVEL
CANCER TREATMENT TECHNOLOGY EXPECTED TO BEGIN IN Q3
* ANPAC BIO-MEDICAL SCIENCE CO LTD - CLASS III MEDICAL
DEVICE
REGISTRATION APPLICATION TO CHINESE NMPA PLANNED FOR Q3 2022
Source text for Eikon: ID:nGNXlSzrJ
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022